Home News & Events Events Events Filter events Filter events by clicking within the ‘Category’ drop-down list. Category - Any -IndustryWebinarsWorkshop In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media Related information: Webpage Webinars Webpage Industry events Webpage Workshops What’s happening in ICON ICON Plc Analysts, rejoice. Metys® offers predefined dashboards for quick answers and a powerful report builder for custom views – plus Excel integration for seamless workflows. It’s market intelligence, your way. Explore Mety... 20h View post View webpage ICON Plc Although advances in antiretroviral therapies are helping to curtail the HIV epidemic, there are limitations introduced by access and adherence. Find out what developers need to know when navigating these obstacles in th... 22h 1 View post View webpage ICON Plc In settings with global HIV treatment disparities, the long-term success of antiretroviral interventions is jeopardised. Discover considerations for developing therapies that overcome obstacles in access, adherence and... 22h View post View webpage ICON Plc How to navigate EU MAA Regulations and Registration. Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter the market it is critical to as... 17 Dec 1 View post View webpage ICON Plc Want to know what’s missing in next-gen drug delivery? In this article for BioPharm International, ICON’s Head of Regulatory CMC, Venkat Sunkara, outlines current product development trends happening in the world of bio... 17 Dec View post View webpage ICON Plc By integrating molecular design, advanced delivery technologies and robust manufacturing practices, pharmaceutical companies can translate cutting-edge biopharmaceuticals into safe, effective therapies that reach patient... 17 Dec 1 View post View webpage ICON Plc USP compounding may be fast — but is it costing you quality, compliance, and insight? In this insightful session, our experts discussed: - Why GMP manufacturing offers a strategic edge in early phase trials - Real-worl... 17 Dec View post View webpage ICON Plc While cardiovascular outcome trials are critical to demonstrating clinical value, they can also be complex and costly. Among the most challenging aspects are the people involved, from patients to investigators and commit... 16 Dec View post View webpage ICON Plc Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp... 16 Dec View post View webpage ICON Plc The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. In the latest blog in our managing risk for medical devices series... 16 Dec 2 View post View webpage ICON Plc Our Creative & Digital Services and Global Medical Communications teams have been honoured for the ISMPP Academy Poster with an Rx Club Award of Excellence in the Posters/Display category. Congratulations for delivering ... 16 Dec 2 View post ICON Plc There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford... 16 Dec View post View webpage
